沪深两市全天主力资金净流出241.26亿元，其中，科创板主力资金净流出54.49亿元，主力资金净流入的 有224只股，主力资金净流出的有376只股。 证券时报·数据宝统计显示，今日科创板个股上涨的有453只，涨停的有信科移动-U、震有科技等3只， 下跌的有141只。 资金流向方面，今日主力资金净流入的科创板股共有224只，其中，12只个股主力资金净流入超亿元， 海光信息主力资金净流入4.57亿元，净流入资金居首；信科移动-U、强一股份紧随其后，全天净流入资 金分别为3.37亿元、3.23亿元。主力资金净流出的有376只，净流出资金最多的是中芯国际，该股今日下 跌0.98%，全天主力资金净流出8.62亿元，其次是中微公司、东芯股份，主力资金净流出分别为5.31亿 元、4.65亿元。 从主力资金连续性进行观察，共有56只个股主力资金连续3个交易日以上持续净流入，连续流入天数最 多的是安旭生物，该股已连续10个交易日净流入；连续净流入天数较多的还有誉辰智能、福昕软件等， 主力资金分别连续流入9天、8天。主力资金连续流出的个股有143只，连续流出天数最多的是达梦数 据，该股已连续23个交易日净流出；连续净流出天数较多 ...

（来源：淘金ETF） 1. 海泰新光（688677） 2. 华强科技（688151） 注册于湖北宜昌，主营业务聚焦特种防护装备、医药包装及医疗器械三大领域，医疗器械板块主打医用 防护用品、医用高分子材料等产品，涵盖医用防护服、口罩、注射器等品类。公司拥有完善的防护医疗 器械生产体系，在公共卫生应急物资保障领域具备核心优势。在脑机接口的医疗场景中，其研发的医用 防护装备可应用于脑机接口植入手术的无菌操作环境，而医用高分子材料也可适配脑机接口设备的生物 相容性部件研发。凭借军工级的生产质控标准，公司在医疗器械细分领域的产品竞争力持续提升。 3. 振德医疗（603301） 总部位于浙江绍兴，是国内医用敷料行业的龙头企业，主营医用敷料、康复护理、手术感控等医疗器械 产品，产品涵盖创口贴、纱布、手术衣、造口袋等全品类医用耗材。公司构建了"医用敷料+感控防护 +康复护理"的产品矩阵，销售网络覆盖全球130多个国家和地区。在脑机接口的临床应用环节，其手术 感控产品可满足脑机接口植入手术的无菌操作要求，康复护理类产品则能适配术后患者的康复管理需 求。2026年随着脑机接口医疗应用落地加速，公司的手术感控耗材业务有望迎来增量市 ...

12月24日，安旭生物涨0.03%，成交额1283.23万元。两融数据显示，当日安旭生物获融资买入额144.65 万元，融资偿还251.52万元，融资净买入-106.87万元。截至12月24日，安旭生物融资融券余额合计 9492.49万元。 融资方面，安旭生物当日融资买入144.65万元。当前融资余额9492.49万元，占流通市值的1.93%，融资 余额低于近一年40%分位水平，处于较低位。 资料显示，杭州安旭生物科技股份有限公司位于浙江省杭州市莫干山路1418-50号4幢5层，成立日期 2008年7月4日，上市日期2021年11月18日，公司主营业务涉及POCT试剂及仪器的研发、生产与销售。 主营业务收入构成为：快速诊断试剂100.00%。 责任编辑：小浪快报 截至9月30日，安旭生物股东户数6090.00，较上期增加1.10%；人均流通股20867股，较上期减少 1.08%。2025年1月-9月，安旭生物实现营业收入3.25亿元，同比减少19.34%；归母净利润6435.86万元， 同比减少52.60%。 分红方面，安旭生物A股上市后累计派现8.95亿元。近三年，累计派现6.57亿元。 机构持仓方面，截止 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-033 一、 募集资金基本情况 根据中国证券监督管理委员会于 2021 年 9 月 28 日出具的《关于同意杭州安旭生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3138 号），公 司获准向社会公开发行人民币普通股 15,333,400 股，每股发行价格为人民币 78.28 元， 募集资金总额为 120,029.86 万元；扣除承销及保荐费用、发行登记费以及其他交易费 用共计 14,445.23 万元（不含增值税金额）后，募集资金净额为 105,584.63 万元，上述 资金已全部到位，经信永中和会计师事务所（特殊普通合伙）审验并于 2021 年 11 月 12 日出具了"XYZH/2021HZAA10537"《验资报告》。 募集资金到账后，已全部存放于 经公司董事会批准开设的募集资金专项账户内，公司已与保荐机构、存放募集资金的 银行签署了募集资金三方监管协议。 二、 募集资金管理情况 杭州安旭生物科技股份有限公司 关于部分募集资金账户注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重 ...

融券方面，安旭生物12月23日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 12月23日，安旭生物涨0.00%，成交额1004.95万元。两融数据显示，当日安旭生物获融资买入额196.84 万元，融资偿还172.68万元，融资净买入24.16万元。截至12月23日，安旭生物融资融券余额合计 9599.36万元。 融资方面，安旭生物当日融资买入196.84万元。当前融资余额9599.36万元，占流通市值的1.95%，融资 余额低于近一年50%分位水平，处于较低位。 资料显示，杭州安旭生物科技股份有限公司位于浙江省杭州市莫干山路1418-50号4幢5层，成立日期 2008年7月4日，上市日期2021年11月18日，公司主营业务涉及POCT试剂及仪器的研发、生产与销售。 主营业务收入构成为：快速诊断试剂100.00%。 截至9月30日，安旭生物股东户数6090.00，较上期增加1.10%；人均流通股20867股，较上期减少 1.08%。2025年1月-9月，安旭生物实现营业收入3.25亿元，同比减少19. ...

Core Insights - The article highlights significant breakthroughs in flow cytometry expected in 2025, with spectral flow cytometry emerging as the mainstream technology, driven by multi-laser, high-channel, and full-spectrum systems that enhance multi-color detection capabilities [1][2] - New technologies such as imaging flow cytometry, Raman spectral flow cytometry, and nano flow cytometry are making notable progress, indicating a shift from "phenotypic analysis" to "structural and functional integration analysis" [2] Product Releases - A total of 13 new flow cytometry products from 11 manufacturers were reported for release in 2025, showcasing advancements in various types of flow cytometry technologies [3] - Key products include: - BD's FlowJo™ v11 flow analysis software, which features a new code architecture and intuitive interface for high-dimensional data mining [10] - Cytek's Aurora™ Evo system, which enhances the capabilities of the previous Aurora system with improved sensitivity and resolution [32] - BaySpec's Endogen 3 Implex, a high-throughput flow cytometer based on coherent Raman spectroscopy, capable of measuring at a rate of up to 24,000 spectra per second [26] Technological Advancements - The FACSDi scover™ A8/A8 FX imaging spectral flow cytometer by BD allows for high-definition imaging of cell morphology and subcellular structures, enhancing the understanding of cell function [7] - The OMNIS ONE by Cytek integrates a 5-laser, 79-channel full-spectrum detection system, achieving over 99% cell viability and 95% single-cell rate post-sorting [13] - The iQue® 5 high-throughput flow cytometer from Sartorius supports up to 27 channels and is designed for continuous operation, significantly reducing operational maintenance time [29] Application Scope - The advancements in flow cytometry technologies are applicable across various fields, including basic research, clinical tumor immune microenvironment analysis, and pathogen fine typing in infectious diseases [9] - The new products are designed to meet diverse laboratory needs, from high-dimensional immune analysis to clinical diagnostics, enhancing the capabilities of researchers and clinicians alike [24][30]

融券方面，当日无融券交易。 融资融券余额9660.93万元，较昨日上涨1.1%。 证券之星消息，12月2日，安旭生物（688075）融资买入290.01万元，融资偿还184.65万元，融资净买入 105.36万元，融资余额9660.93万元，近3个交易日已连续净买入累计329.57万元，近20个交易日中有13 个交易日出现融资净买入。 小知识 融资融券：融资余额增加反映市场做多情绪强化，融资余额减少反映市场观望情绪或者看空情绪强化； 相应的，融券余额增加反映市场看空情绪增强，融券余额减少反映市场观望情绪增强或者看多情绪增 强。需注意的是，由于融资融券的财务杠杆效应，融资融券对投资者来说也是一把双刃剑，好比放大镜 一般，盈利情况下，利润会成倍增长，亏了也能把亏损放大很多。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-12-02 | 9660.93万 | 105.36万 | 1.10% | | 20 ...

Core Viewpoint - Anxu Bio announced on November 24 that it will disclose the number of shareholders in its regular reports [2] Group 1 - The company will provide shareholder data in its periodic reports [2]

Core Points - Anxu Bio announced that shareholder Ma Huaxiang plans to reduce his holdings by up to 1,200,000 shares, which represents no more than 0.94% of the company's total share capital [1] - The reduction will occur through centralized bidding transactions and will not exceed 1.00% of the total shares within any consecutive 90-day period [1] - The share reduction period will commence 15 trading days after the announcement and will last for three months [1]

Core Insights - On November 18, several companies disclosed their shareholding changes, with 康缘药业, 超达装备, and 海大集团 announcing share buybacks, while 15 companies, including 立达信 and 艾布鲁, reported share reductions [1][2]. Group 1: Share Buybacks - 康缘药业's actual controller and director, 肖伟, increased his shareholding by 20,000 shares [2]. - 超达装备 secured a stock repurchase loan commitment from China Bank for up to 450 million yuan [2]. - 海大集团 plans to repurchase shares worth no less than 1 billion yuan and up to 1.6 billion yuan [2]. Group 2: Share Reductions - 立达信's shareholder, 李春华, intends to reduce his stake by no more than 1.56% [2]. - 艾布鲁's controlling shareholder, 钟儒波, plans to reduce his stake by no more than 3% [2]. - 高德红外's actual controller, 黄立, aims to reduce his stake by no more than 3% [2]. - 嘉美包装's shareholders plan to collectively reduce their stake by no more than 1.16% [2]. - 蓄奥规划's shareholders intend to reduce their stake by no more than 1% [2]. - 君逸数码's shareholder, 成都高创投, plans to reduce his stake by no more than 1% [2]. - 联合水务's shareholder, 上海衡联, intends to reduce his stake by no more than 0.14% [2]. - 亚翔集成's second-largest shareholder has reduced 130,000 shares and is still in the reduction period [2]. - 芯朋微's controlling shareholder, 张立新, has terminated his reduction plan early [2]. - 安旭生物's shareholder, 马华祥, plans to reduce his stake by no more than 0.94% [2]. - 农心科技's shareholder, 宁波农旗, intends to reduce his stake by no more than 0.54% [2]. - 禾川科技's actual controller and others plan to reduce their stake by no more than 6% [2]. - 世龙实业's shareholder, 电化高科, plans to reduce his stake by no more than 3% [2]. - 中国化学's executive, 聂宁新, intends to reduce his stake by no more than 60,000 shares [2]. - 鸿泉技术's shareholder, 千方科技, plans to reduce his stake by no more than 3% [2].